Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3882291 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL3884627 | 1.00 | MAPK13 (0.46) | MAPK13MAPK12MAPK11MAPK14KIT | |
| Tert-Butyl Formate SCHEMBL27563639 | 0.85 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL4781601 | 0.82 | PRKCQ (0.41) | MAPK13MAPK12MAPK11MAPK14HRH4 | |
| SCHEMBL2385053 | 0.81 | MAPK13 (0.43) | MAPK13MAPK12MAPK11MAPK14LMNA | |
| SCHEMBL3707817 | 0.80 | TRPV1 (0.47) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL232057 | 0.80 | TRPV1 (0.47) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL232058 | 0.80 | TRPV1 (0.47) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL2897789 | 0.77 | MAPT (0.42) | MAPK13MAPK12MAPK11MAPK14KIT | |
| SCHEMBL16439229 | 0.77 | ALDH1A1 (0.46) | MAPK13MAPK12MAPK11MAPK14KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| CN-1305871-C | For the treatment of 5-HT2APiperazinyl-pyrazinone derivatives for receptor related diseases | BIOVITRUM AB (SE) | 2007-03-21 | — | — | CN | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| CN-1823057-A | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORP (US) | 2006-08-23 | — | — | CN | disclosed |
| CN-1675198-A | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2a receptor-related disorders | BIOVITRUM AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | MAPK13 3685/4885MAPK12 4161/4885MAPK11 3219/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MAPK13 3283/4885MAPK12 3462/4885MAPK11 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.